Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
07. November 2024 16:05 ET
|
Evoke Pharma, Inc.
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52%...
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
28. Oktober 2024 07:00 ET
|
Evoke Pharma, Inc.
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All...
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
23. Oktober 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
22. Oktober 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
01. Oktober 2024 08:30 ET
|
Evoke Pharma, Inc.
Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc....
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
19. September 2024 14:20 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
09. September 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
04. September 2024 09:20 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
13. August 2024 08:00 ET
|
Evoke Pharma, Inc.
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills...
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
08. August 2024 08:30 ET
|
Evoke Pharma, Inc.
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug....